Suppr超能文献

5-氨基水杨酸类药物所致急性胰腺炎的回顾性匹配队列分析

Retrospective Matched-Cohort Analysis of Acute Pancreatitis Induced by 5-Aminosalicylic Acid-Derived Drugs.

作者信息

Meczker Ágnes, Mikó Alexandra, Gede Noémi, Szentesi Andrea, Párniczky Andrea, Gódi Szilárd, Hegyi Péter

机构信息

Division of Translational Medicine, First Department of Medicine, University of Pécs, Medical School.

出版信息

Pancreas. 2019 Apr;48(4):488-495. doi: 10.1097/MPA.0000000000001297.

Abstract

OBJECTIVES

This study aimed to compare the clinical course of 5-aminosalicylic acid-derived, drug-induced acute pancreatitis (5-ASA-DIAP) to acute pancreatitis (AP) caused by other etiologies.

METHODS

A cohort of patients with 5-ASA-DIAP was established through literature search. As a control AP (CAP) group, a cohort was generated from a registry. Data on the diagnostic procedure, symptoms, enzyme elevation, imaging, severity, and recovery parameters were collected. Causality was assessed using the Naranjo algorithm.

RESULTS

Twenty-nine articles were included, which describe 36 patients with fifty-one 5-ASA-DIAP episodes (60.78% female, 39.22% male). There were 88.2% mild, 3.92% moderate, and 7.84% severe cases of AP in the 5-ASA-DIAP group, and 70.6%, 25.5%, and 3.92% such cases in the CAP population, respectively. Symptoms improved significantly faster (mean ± SE, 2.5 ± 0.34 vs 3.74 ± 0.42 days; P = 0.018); however, pancreatic enzyme levels normalized significantly more slowly (6.27 ± 1.53 vs 3.63 ± 0.61 days, P = 0.008) in the 5-ASA-DIAP cohort compared with the CAP group. This study confirms that there are no diagnostic differences between 5-ASA-DIAP and AP of other etiologies.

CONCLUSIONS

Fewer moderate but more severe cases were found in the 5-ASA-DIAP group; therefore, 5-ASA-DIAP must be taken as seriously as AP of other etiologies.

摘要

目的

本研究旨在比较5-氨基水杨酸所致药物性急性胰腺炎(5-ASA-DIAP)与其他病因引起的急性胰腺炎(AP)的临床病程。

方法

通过文献检索建立5-ASA-DIAP患者队列。作为对照AP(CAP)组,从登记处生成一个队列。收集有关诊断程序、症状、酶升高、影像学、严重程度和恢复参数的数据。使用纳伦霍算法评估因果关系。

结果

纳入29篇文章,描述了36例患者发生51次5-ASA-DIAP发作(女性占60.78%,男性占39.22%)。5-ASA-DIAP组中AP的轻度、中度和重度病例分别为88.2%、3.92%和7.84%,CAP人群中此类病例分别为70.6%、25.5%和3.92%。症状改善明显更快(均值±标准误,2.5±0.34天 vs 3.74±0.42天;P = 0.018);然而,与CAP组相比,5-ASA-DIAP队列中胰腺酶水平恢复正常明显更慢(6. – 27±1.53天 vs 3.63±0.61天,P = 0.008)。本研究证实5-ASA-DIAP与其他病因的AP之间在诊断上没有差异。

结论

5-ASA-DIAP组中中度病例较少但重度病例较多;因此,必须像对待其他病因的AP一样认真对待5-ASA-DIAP。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/478a/6493669/2bf86d810fcf/mpa-48-488-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验